TAS 205

Drug Profile

TAS 205

Alternative Names: TAS-205

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 17 Oct 2017 Taiho Pharmaceutical completes a phase II trial in Duchenne muscular dystrophy (In adolescents, In children) in Japan (PO) (NCT02752048)
  • 01 May 2016 Phase-II clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Japan (PO) (NCT02752048 and Otsuka Pharmaceuticals pipeline, September 2016)
  • 21 Apr 2016 Taiho Pharmaceutical plans a phase IIa trial for Duchenne muscular dystrophy (In adolescents, In children, In adults) in Japan (PO) (NCT02752048)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top